Clinical trials: Coronary Stent Restenosis
In-stent Restenosis Lesion, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis
This study aims to evaluate, through a multicenter, prospective, double-blind, randomized, placebo-controlled clinical trial, whether immunosuppressive therapy improves target lesion-related cardiovascular outcomes compared to…
- Trial name
- STOP-RECUR (NCT06981845)
- Testing
- Immunosuppressive therapy
- Volunteers
- 52 people
- Sponsor
- China National Center for Cardiovascular Diseases
In-stent Coronary Artery Restenosis
Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST)
The purpose of this study is to assess safety and efficacy of the Danubio Paclitaxel Eluting Balloon for the treatment of In-Stent Restenosis lesions in native coronary arteries.
- Trial name
- DEBREST (NCT01485068)
- Testing
- Danubio paclitaxel-eluting balloon
- Where
- 8 sites in France
- Volunteers
- 44 people
- Sponsor
- MINVASYS
Coronary Disease
The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis
The purpose of this study is to evaluate the efficacy of 3 different drug-eluting-stent platforms to reduce coronary artery reblockage after stent implantation
- Trial name
- ISAR-TEST-2 (NCT00332397)
- Testing
- Rapamycin-eluting Stent, Zotarolimus-eluting Stent
- Where
- 2 sites in Germany
- Volunteers
- 1,007 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Metal Allergy, Contact Allergy
Metal Allergy In-Stent Restenosis Study
In-stent restenosis remains one of the most challenging problems in patients after coronary artery angioplasty. Angiographically, it is discovered in 10% of the patients after drug-eluting stent (DES) implantation.
- Conditions
- Metal Allergy, Contact Allergy, Restenoses, Coronary, In-stent Restenosis
- Trial name
- RESTALL (NCT03588962)
- Testing
- In-stent restenosis
- Volunteers
- 1,000 people
- Sponsor
- Silesian Centre for Heart Diseases
Restenosis or Adverse Cardiovascular Event
Endothelial Function and Heart Rate Variability After Stenting
The objective of this study is to evaluate whether impaired endothelial function and low heart rate variability are associated with clinical restenosis after percutaneous coronary intervention with stent implantation in patients…
- Trial name
- FUNKIS (NCT00999323)
- Testing
- stent implantation in coronary artery
- Where
- Norway
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Atherosclerosis, Restenosis
Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis
clinically relevant in stent restenosis occurs in 5-10% of the non-diabetic patients treated with a coronary bare metal stent. Recent research has identified endothelial progenitor cells as well as dendritic cells as components…
- Trial name
- NCT00493597
- Where
- Belgium
- Volunteers
- 124 people
- Sponsor
- University Hospital, Antwerp
Ischemic Heart Disease, Stable Angina
DANish Multicenter STENT Trial
The purpose of the study was to evaluate procedural and late outcome of coronary artery stenting using 2 different unmounted stents
- Conditions
- Ischemic Heart Disease, Stable Angina, Unstable Angina
- Trial name
- NCT00139802
- Testing
- Coronary Stent Implantation
- Where
- Denmark
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
In-stent Restenosis
Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)
To demonstrate acceptable short term safety rates of the Drug-eluting Coronary Spur Stent System as a primary treatment for coronary in-stent restenosis.
- Trial name
- NCT06117150
- Testing
- Drug-eluting Coronary Spur Stent System
- Where
- 2 sites in New Zealand
- Volunteers
- 9 people
- Sponsor
- ReFlow Medical, Inc.
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon
This Clinical Evaluation Report (CER) covers the Mamba Sirolimus-Eluting PTCA Balloon catheter intended for the treatment of coronary artery disease in de novo or in-stent restenosis lesions.
- Trial name
- NCT07326735
- Testing
- Mamba Sirolimus-Eluting PTCA Balloon, Percutaneous Coronary Angioplasty with Sirolimus-Coated Balloon
- Where
- 2 sites in Burma, Malaysia
- Volunteers
- 360 people
- Sponsor
- Frisch Medical Device Private Limited
In-stent Restenosis
Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter
Study purpose The safety and efficacy of paclitaxel controlled release balloon catheter Vasoguard TM in treatment of in-stent restenosis.
- Trial name
- NCT02891018
- Testing
- paclitaxel controlled release balloon catheter Vasoguard TM, paclitaxel release coronary balloon catheter SeQuent Please
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Shandong Branden Med.Device Co.,Ltd
Vertebral Artery Stenosis
Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents
Vertebral artery stenosis (VAS) decreases posterior brain perfusion, causing vertebrobasilar insufficiency (VBI). It is also an important embolic source to the posterior brain.
- Trial name
- NCT00172458
- Where
- Taiwan
- Sponsor
- National Taiwan University Hospital
Coronary Disease
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™…
- Trial name
- NCT00165035
- Testing
- CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- Where
- 2 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- Cordis US Corp.
Coronary Occlusion, Thrombosis (Stent Thrombosis)
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
This is a prospective, randomized, active-controlled, open label, parallel two-arm, multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER SELECT PLUS Sirolimus-Eluting Coronary Stent System…
- Conditions
- Coronary Occlusion, Thrombosis (Stent Thrombosis), Vascular Disease, Myocardial Ischemia
- Trial name
- NCT01178268
- Testing
- XIENCE V EECSS, CYPHER SELECT PLUS SECSS
- Where
- 2 sites in China
- Volunteers
- 546 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Austrian Multivessel Taxus-Stent Registry
The aim of AUTAX study is to investigate the frequency of MACCE in patients with multivessel disease and multiple Taxus stent implantations in the "real world" stenting at 30 days, 6 and 12 months at 2 year follow-up.
- Trial name
- AUTAX (NCT00738686)
- Testing
- Intracoronary stent implantation
- Where
- 7 sites in Austria
- Volunteers
- 441 people
- Sponsor
- Medical University of Vienna
Coronary Stenosis
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple…
- Trial name
- NCT00301522
- Testing
- TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2
- Where
- 72 sites in United States
- Volunteers
- 1,108 people
- Sponsor
- Boston Scientific Corporation
Coronary Restenosis
SELUTION SLR™ 014 In-stent Restenosis
Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or Drug-Eluting Stent (DES) and qualifying evidence for In-stent Restenosis (ISR) will…
- Trial name
- SELUTION4ISR (NCT04280029)
- Testing
- SELUTION SLR 014 DEB, Standard of Care
- Where
- 48 sites in United States, Belgium and 5 more
- Volunteers
- 418 people
- Sponsor
- M.A. Med Alliance S.A.
Angina, Chronic Coronary Occlusion
XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan
The objectives of this post-marketing surveillance, conducted in Japan, is to know the frequency, type and degree of device malfunction, to assure the safety of the medical device, and to collect information on evaluation of the…
- Conditions
- Angina, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease
- Trial name
- NCT01086228
- Testing
- XIENCE V / PROMUS stent
- Where
- 47 sites in Japan
- Volunteers
- 2,010 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent
To evaluate that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-converting enzyme receptor blockers (ARBs) reduce the risk of restenosis after DES implantation.
- Trial name
- VAL-SUPPRES (NCT00589732)
- Testing
- Valsartan
- Where
- 5 sites in South Korea
- Volunteers
- 220 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease, Angina Pectoris
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Unstable Angina Pectoris, Acute Coronary Syndrome
- Trial name
- BIONYX (NCT02508714)
- Testing
- Orsiro, Resolute Onyx
- Where
- 7 sites in Belgium, Israel and 1 more
- Volunteers
- 2,470 people
- Sponsor
- Thorax Centrum Twente
Coronary Artery Disease
SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent
The objective of Series III Run-In Trial is to compare the performance and efficacy of the Supralimus® sirolimus-eluting stent with the Xience V™ everolimus-eluting stent with respect to in-stent luminal late loss at 9 months as…
- Trial name
- NCT00917163
- Testing
- Supralimus(R) Sirolimus-Eluting Coronary Stent System, Xience V™ Everolimus Eluting Coronary Stent
- Where
- 28 sites in Brazil, India and 1 more
- Volunteers
- 13 people
- Sponsor
- Sahajanand Medical Technologies Limited